Agios has moved its international headquarters to Zug, announced the canton of Zug in a statement. Company representatives were impressed by life science innovation in the region, according to the statement. The talented workforce also persuaded the move.
Orlando Oliveira, Vice President of Agios, highlighted other key factors behind the decision: the centrality in Europe, great infrastructure, outstanding quality of life and great support from the local authorities.
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases. A leader in the field of cellular metabolism, the company was founded in 2008 in Cambridge in the US state of Massachusetts. It is listed on the American Nasdaq stock exchange.